Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-095-9 | CAS number: 7439-88-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 8 Sept - 1 Oct 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Version / remarks:
- v 17 December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- Version / remarks:
- v 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- no
Test material
- Reference substance name:
- Iridium
- EC Number:
- 231-095-9
- EC Name:
- Iridium
- Cas Number:
- 7439-88-5
- Molecular formula:
- Ir
- IUPAC Name:
- iridium(3+)
- Details on test material:
- Iridium
Constituent 1
- Specific details on test material used for the study:
- powder
purity >99.95%
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Wistar Han
Females were nulliparous and non-pregnant
age at beginning of treatment: 8 - 12 weeks
Acclimatization:At least 5 days prior to the start of dosing under test conditions after health examination. Only animals without any visible signs of illness were used for the study.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 1%
- Details on oral exposure:
- Dose administration was once orally by gavage (feeding needle). The volume administered did not exceed 10 mL/kg b.w.
- Doses:
- Based on available information on the toxicity of the test item, 300 mg/kg was chosen as the initial starting dose, since a severe toxicity which may necessitate humane euthanasia was not expected at this dose level.
In the absence of mortality or toxicity at a dose level of 2000 mg/kg, an additional group of animals was treated - No. of animals per sex per dose:
- DRF: 1 female at 300 mg/kg, 1 female at 2000 mg/kg
Main test: 4 additional females at 2000 mg/kg - Control animals:
- no
- Details on study design:
- Clinical observations and inspections for morbidity / mortality were performed at least three times within the first six hours after application (i.e., 30 minutes and 1 hour, 2 hours and 4 hours after dosing on day 0), thereafter at least once daily for 14 days. All surviving animals were observed for 14 days after dosing.
The nature and severity, where appropriate, of the clinical signs and the time were recorded at each observation for all individual animals. If applicable, the time of death/humane kill was recorded as precisely as possible. Observations included changes in the skin and fur, eyes and mucous membranes, and respiratory, circulatory, autonomic and central nervous system, and somatomotor activity and behavior pattern. Particular attention was directed to the observation of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma.
Body weights were recorded on Day 0 (prior to dosing), Day 7, and 14, or (if applicable) at death (unscheduled).
A gross necropsy was performed on all animals that died or were humanely killed during the study (if applicable) and at the end of the in-life part. Any macroscopic abnormalities were recorded. Routinely no organs or tissues were retained. - Statistics:
- The test item is classified according to Annex 3 of the OECD Guidelines for Testing of Chemicals No. 420 ‘Acute Oral Toxicity – Fixed Dose Procedure’ (adopted 17 December 2001) as shown in the Flow Chart in Annex 2.
Evaluation of data includes the identification of the number of animals that died during the study (or that were killed for humane reasons), and determination of the nature, severity, onset and duration of the toxic effects. If possible, the signs of toxic effects of evident toxicity are described. Evident toxicity refers to the toxic effects of sufficient severity that administration of the next higher dose level could result in development of severe signs of toxicity and probable mortality. Effects on body weights and abnormalities noted at necropsy were identified.
Using the mortality data obtained, an estimate of the acute oral median lethal dose (LD50) of the test item was made.
Results and discussion
- Preliminary study:
- Two single animals were treated as follows:
Dose level (mg/kg) Concentration (mg/mL) Dose volume (mL/kg) Number of rats
Female
300 30 10 1
2000 200 10 1
In the absence of mortality or toxicity at a dose level of 2000 mg/kg, an additional group of animals (4 females) was treated at 2000 mg/kg.
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths during the study.
- Clinical signs:
- other: 300 mg/kg: Clinical signs observed were secretion of Haderian glands on day 4 and 5. No further clinical signs were noted. 2000 mg/kg: Secretion of Harderian glands was noted in two animals. The fur of one animal was stained with the test item. Additiona
- Gross pathology:
- 300 mg/kg: No abnormalities were noted at the macroscopic examination at study termination on Day 14.
2000 mg/kg: Small scratches in the scapula region were noted for three animals. One animal showed staining of the dorsum caused by secretion of Harderian glands. In four animals an increased amount of saliva in the mouth including a wet snout was observed. Two animals had a knot of size 3x4 mm on the thymus and for one animal a cystic kidney was noted. No other abnormalities were noted at necropsy.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute median lethal oral dose (LD50) to rats of Iridium was demonstrated to be greater than 2000 mg/kg body weight.
- Executive summary:
A study was performed to assess the acute oral toxicity of Iridium to the rat.
Following a sighting test at a dose levels of 300 mg/kg b.w. and 2000 mg/kg b.w. in one female rat per dose group, a further group of four fasted females was given a single oral dose of Iridium, as a suspension in 1% Carboxymethylcellulose (CMC), at a dose level of 2000 mg/kg body weight. Clinical signs and body weight development were monitored in all animals during the study. All animals were subjected to gross necropsy.
Mortality:There were no deaths.
Clinical Observations:Secretion of Harderian glands was noted (in one animal dosed at 300 mg/kg b.w. and two animals dosed at 2000 mg/kg b.w.) on several days. The fur of one animal (2000 mg/kg b.w.) was stained with test item on the day of application and for this animal a small scratch in the scapula region was observed. There were no signs of systemic toxicity noted in the remaining animals.
Body Weight:All animals showed expected gains in body weight.
Necropsy:Small scratches in the scapula region were noted in three animals. One animal showed staining of the dorsum caused by secretion of Harderian glands. In four animals an increased amount of saliva in the mouth including a wet snout was observed. Two animals had a knot of size 3x4 mm on the thymus and for one animal a cystic kidney was noted.No other abnormalities were noted at necropsy.
The acute median lethal oral dose (LD50) to rats of Iridium was demonstrated to be greater than 2000 mg/kg body weight.
Iridium is not classified for acute toxicity (oral) according to CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.